RESUMO
INTRODUCTION AND OBJECTIVES: A problem in the interpretation of noninvasive urine tests for detection of bladder carcinoma is the finding of false-positive results. Several authors have described that patients with false-positive results are at high risk for tumor recurrence or progression. Only few data are available for comparing the clinical course of patients with false-positive test results and patients with true-negative results. We studied whether patients with false-positive results of various urine test had a higher recurrence rate than patients with true-negative results. METHODS: Urine samples from 61 patients without evidence of active bladder carcinoma were included. Of the 61 patients, 51 had a history of bladder cancer, and 10 underwent transurethral resection for suspect of bladder carcinoma but had negative pathologic findings. Immunocytology (Lewis X and 486p3/12) was performed on bladder washings, and BTAstat and NMP22 were performed on urine samples. RESULTS: During the follow-up period, 22 patients had one or more false-positive BTAstat test results, 25 patients had one or more false-positive NMP22 tests, 42 patients had at least one false-positive Lewis X test, and 11 patients had one or more false-positive 486p3/12 test. During a follow-up period of 3-39 months (median, 17.6 months) four patients expected a tumor recurrence. Among patients with false-positive urine test results 2 of 22 (9.1%, BTAstat), 2 of 25 (8%, NMP22), 4 of 42 (9.5%, Lewis X), and 3 of 11 (27.2%, 486p3/12) suffered from tumor recurrence. In contrast, among patients with true-negative test results 2 of 39 (5.2%, BTAstat), 2 of 36 (5.6%, NMP22), 0 of 18 (0%, Lewis X), 1 of 50 (2.0%, 486p3/12) had a tumor recurrence. CONCLUSIONS: Patients with a false-positive urine test result do not generally have a greater risk of tumor recurrence or progression than patients with a true-negative result. In our series, only patients with false-positive 486p3/12 test result had a higher recurrence rate. Our findings do not justify a more aggressive adjuvant treatment or surveillance for patients with false-positive urine tests.
Assuntos
Antígenos de Neoplasias/urina , Biomarcadores Tumorais/urina , Antígenos CD15/urina , Proteínas Nucleares/urina , Neoplasias da Bexiga Urinária/patologia , Anticorpos Monoclonais , Reações Falso-Positivas , Seguimentos , Humanos , Técnicas Imunoenzimáticas , Estadiamento de Neoplasias , Valor Preditivo dos Testes , PrognósticoRESUMO
BACKGROUND: Different analytical concepts were introduced to quantify the changes of the electroencephalogram. The Datex-Ohmeda S/5 Entropy Module (Datex-Ohmeda Division, Instrumentarium Corp., Helsinki, Finland) was the first commercial monitor based on the entropy generating two indices, the state entropy (SE) and the response entropy (RE). The aim of the current study was to compare the accuracy of SE and RE with the Bispectral Index(R) monitor (BIS(R); Aspect Medical Systems, Newton, MA) during propofol-remifentanil anesthesia. METHODS: The authors investigated 20 female patients during minor gynecologic surgery. SE, RE, BIS, mean arterial blood pressure, heart rate, and sedation level were recorded every 20 s during stepwise increase (target-controlled infusion, 0.5 microg/ml) of propofol until the patients lost response. Five minutes after loss of response, remifentanil infusion (0.4 microg . kg(-1) . min(-1)) was started. Spearman correlation coefficient and prediction probability were calculated for sedation levels with SE, RE, BIS, mean arterial blood pressure, and heart rate. The ability of the investigated parameters to distinguish between the anesthesia steps awake versus loss of response, awake versus anesthesia, anesthesia versus first reaction, and anesthesia versus extubation was analyzed with the prediction probability. RESULTS: SE correlates best with sedation levels, but no significant differences of the prediction probability values among SE, RE, and BIS were found. The prediction probability for all investigated steps of anesthesia did not show significant differences among SE, RE, and BIS. SE, RE, and BIS were superior to mean arterial blood pressure and heart rate. CONCLUSION: SE, RE, and BIS revealed similar information about the level of sedation and allowed the authors to distinguish between different steps of anesthesia. Both monitors provided useful additional information for the anesthesiologist.
Assuntos
Anestesia Intravenosa , Anestésicos Intravenosos , Eletroencefalografia/efeitos dos fármacos , Eletroencefalografia/instrumentação , Monitorização Intraoperatória/instrumentação , Piperidinas , Propofol , Estimulação Acústica , Adulto , Algoritmos , Anestesia Geral , Pressão Sanguínea/efeitos dos fármacos , Sedação Consciente , Estado de Consciência/efeitos dos fármacos , Entropia , Feminino , Procedimentos Cirúrgicos em Ginecologia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Intubação Intratraqueal , Modelos Logísticos , Pessoa de Meia-Idade , Dor/fisiopatologia , Estimulação Física , Valor Preditivo dos Testes , RemifentanilRESUMO
Despite several new urine markers urinary cytology remains the gold standard for the non-invasive detection of bladder carcinoma. The use of monoclonal antibodies against tumor associated antigens offers a promising approach to improve urinary cytology. The aim of this study was to compare fluorescence immunocytology (ImmunoCyt/Ucyt+ test), alone and in combination with the conventional cytology, with other urine markers. Urine samples from 126 patients undergoing cystoscopy were included in the study. Among them, 42 patients had urothelial carcinoma, two dysplasia, two other malignancies, and 78 had no evidence of bladder cancer. Urine samples were taken before any manipulation. We used the ImmunoCyt test and Papanicolaou staining for conventional cytology. The ImmunoCyt slides were examined under a fluorescence microscope. Evaluations of the tests were blinded to clinical and pathological data and were carried out by three independent observers. The results of cytology and ImmunoCyt were compared with the BTAstat, NMP22, Lewis X, 486p3/12, and Urovision tests. The sensitivity for the ImmunoCyt test was 78.3% and for conventional cytology 84.6%. The combination of ImmunoCyt and cytology showed a sensitivity of 89.1%. The specificity was 73.8% for the ImmunoCyt alone, 80.0% for the cytology, and 72.5% for the combination of ImmunoCyt and cytology. Sensitivities for the other tests were 68.8% for (FISH), 66.6% (BTA-Stat), 68.8% (486p3/12), 95.5% (Lewis X), and 71.1% for (NMP22). Specificity was 89.1% for (FISH), 78.2% (BTA-Stat), 76.4% (486p3/12), 32.8% (Lewis X), and 65.5% for (NMP22). Urinary cytology can be improved by immunostaining with monoclonal antibodies against tumor-associated antibodies. The combination of ImmunoCyt with conventional cytology offers a superior sensitivity to other commercial tests. The ImmunoCyt test provides a useful supplement to urinary cytology in the diagnosis of bladder cancer.
Assuntos
Neoplasias da Bexiga Urinária/patologia , Urina/citologia , Imunofluorescência , Seguimentos , Humanos , Estadiamento de Neoplasias , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
PURPOSE: The noninvasive detection of urothelial carcinoma remains challenging. We prospectively evaluated urine markers for bladder carcinoma. We compared the NMP22 (Matritech, Cambridge, Massachusetts) and BTA Stat (Bard Diagnostics, Redmond, Washington) tests with immunocytology using mAbs 486p3/12 and BG7 against Lewis X antigen. MATERIALS AND METHODS: The NMP22 and BTA Stat tests were performed in urine samples and immunocytology with mAbs 486p3/12 and BG7 staining were performed in bladder washing specimens in 146 samples of 115 patients undergoing transurethral resection for suspected bladder carcinoma (70) or 45 undergoing followup cystoscopy for a history of bladder carcinoma (76). Bladder carcinoma was detected in 54 patients, including stages pTa in 25, pT1 in 20, pT2 in 8 and carcinoma in situ in 1, while 61 had no evidence of bladder carcinoma. The cutoff was 10 units per ml. for the NMP22, 30% positive cells for 486p3/12 and 5% positive cells for the Lewis X tests. RESULTS: BTA Stat was positive in 65 samples (44.5%) and NMP22 was positive in 69 (47.3%). Immunocytology with mAbs 486p3/12 and BG7 against Lewis X was positive in 52 (35.6%) and 109 (74.7%) samples, respectively. Sensitivity was 70.3% for BTA Stat, 68.5% for NMP22, 68.5% for 486p3/12 and 94.4% for Lewis X. Specificity was 70.6% for BTA Stat, 65.2% for NMP22, 83.6% for 486p3/12 and 36.9% for Lewis X. Area under the receiver operating characteristics curve was 0.6804 for NMP22, 0.7226 for Lewis X and 0.8002 for 486p3/12. False-positive results on BTA Stat in 2 of 22 patients (9%), on NMP22 in 2 of 25 (8%), on 486p3/12 in 3 of 11 (27%) and on Lewis X in 4 of 43 (9.3%) were associated with tumor recurrence. Furthermore, negative results on BTA Stat in 2 of 39 patients (2%), on NMP22 in 2 of 36 (0.5%), on Lewis X in 0 of 18 (0%) and on 486p3/12 in 1 of 50 (2%) was associated with tumor recurrence during followup. CONCLUSIONS: Immunocytology with mAbs against Lewis X showed higher sensitivity than all commercially available tests evaluated. Because of its high sensitivity and high negative predictive value, it may be useful for screening in a high risk population. Patients with a false-positive 486p3/12 test results are at increased risk for tumor recurrence compared with those with negative results.